A User ’s Guide to De-Escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease

We found the review written by Hirten et  al1 timely, published at the height of the COVID-19 pandemic, when pervasive concerns about immunomodulators or biologic drugs prevailed. In the review, the authors present a practical guide to de-escalating patients with evidence to support who to de-escalate and what happens after de-escalation. We would like to caution against a monodimensional approach to de-escalation. First, only the detrimental aspect of outcomes was considered (ie, the risk of relapse).
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research